Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy

Reduction of Renal Uptake of Radiolabeled Octreotate by Amifostine Coadministration

(2012) M. Melis et al.   JOURNAL OF NUCLEAR MEDICINE

Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy

(2012) Peter Kletting et al.   MEDICAL PHYSICS

The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy

(2011) Jean-Mathieu Beauregard et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

68Ga-DOTATOC PET/CT and somatostatin receptor (sst1–sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax

(2011) Christian Boy et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Optimal preloading in radioimmunotherapy with anti-CD45 antibody

(2011) Peter Kletting et al.   MEDICAL PHYSICS

Dependence of the anti-CD66 antibody biodistribution on the dissociation constant: A simulation study

(2011) Peter Kletting et al.   Zeitschrift fur Medizinische Physik

Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model

(2010) P. Kletting et al.   JOURNAL OF NUCLEAR MEDICINE

Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention

(2010) E. Vegt et al.   JOURNAL OF NUCLEAR MEDICINE

In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass

(2010) Irina Velikyan et al.   NUCLEAR MEDICINE AND BIOLOGY

Physical aspects of scintigraphy-based dosimetry for nuclear medicine therapy

(2010) L. Geworski et al.   NUKLEARMEDIZIN-NUCLEAR MEDICINE

Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy

(2010) Stefan E. Pool et al.   SEMINARS IN NUCLEAR MEDICINE

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study

(2009) J. B. Cwikla et al.   ANNALS OF ONCOLOGY

Physiologically Based Modelling and Prediction of Drug Interactions

(2009) Frédéric Y. Bois   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

(2009) Dik J Kwekkeboom et al.   ENDOCRINE-RELATED CANCER

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues

(2009) Edgar J. Rolleman et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Derivation of a Compartmental Model for Quantifying 64Cu-DOTA-RGD Kinetics in Tumor-Bearing Mice

(2009) G. Z. Ferl et al.   JOURNAL OF NUCLEAR MEDICINE

Improving Anti-CD45 Antibody Radioimmunotherapy Using a Physiologically Based Pharmacokinetic Model

(2009) P. Kletting et al.   JOURNAL OF NUCLEAR MEDICINE

Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues

(2009) B. Waser et al.   JOURNAL OF NUCLEAR MEDICINE

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

(2009) M. M. Schmidt et al.   MOLECULAR CANCER THERAPEUTICS

Comparing time activity curves using the Akaike information criterion

(2009) Peter Kletting et al.   PHYSICS IN MEDICINE AND BIOLOGY